Thus, alternatively targeting the CPCM components and the interactions of c-Myc-Max, c-MYc-p300 and p300-CARM1 may be options for developing medicines to inhibit c-Myc downstream targets in CRC. The gene discussed is MAX; the disease is colorectal carcinoma.